News for Dyne Therapeutics, Inc. (DYN)

Strengths: Innovative FORCE platform and robust product pipeline with potential for addressing unmet medical needs.Weaknesses: High operational costs and accum

Dyne Therapeutics reports Q4 EPS of -$0.88. Learn about their R&D spending, financial outlook, and funding plans projected into 2026.

Summary Dyne Therapeutics Inc (DYN), a clinical-stage company focused on neuromuscular diseases, announced significant advancements in its clinical trials and f

- Received FDA Fast Track Designation for DYNE-101 in DM1 - - Full enrollment of Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 Planned

Dyne Therapeutics Inc (DYN), a clinical-stage company focused on developing therapeutics for genetically driven neuromuscular diseases, announced its participat

Insightful Analysis of Jefferies Group (Trades, Portfolio)'s Fourth Quarter 2024 13F Filing Jefferies Group (Trades, Portfolio) recently submitted its 13F fili

Significant Transaction in Biotechnology Sector On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) executed a noteworthy transaction by acquiri

**media[541128]**

On December 31, 2024, RTW INVESTMENTS, LP (Trades, Portfolio) made a significant move by reducing its stake in Dyne Therapeutics Inc (DYN) by 1,600,000 shares.

Dyne Therapeutics (DYN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Transaction Overview On December 31, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, executed a significant transaction involving Dyne Therapeut

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at where Dyne Therapeutics, Inc.

Dyne Therapeutics Inc (DYN), a clinical-stage company specializing in neuromuscular disease therapeutics, announced on February 3, 2025, that its management wil

WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. ( DYN), a clinical-stage neuromuscular disease company focused on advancing innovati

Dyne Therapeutics Inc. (DYN) saw a significant stock price decline of 5.13%, currently trading at $27.93 with a trading volume of 242,038 shares and a turnover

UBS sees LEM Holding stock poised for upside with rising sales and strong ROIC

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 2% on Tuesday. The Dow traded down 1.49% to 40,944.47 while the NASDAQ fell...

Shares of Recursion Pharmaceuticals, Inc. RXRX dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptom...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 1% on Tuesday. The Dow traded down 0.94% to 41,173.76 while the NASDAQ f...